Cargando…

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Detalles Bibliográficos
Autores principales:	Dejnirattisai, Wanwisa, Shaw, Robert H, Supasa, Piyada, Liu, Chang, Stuart, Arabella SV, Pollard, Andrew J, Liu, Xinxue, Lambe, Teresa, Crook, Derrick, Stuart, Dave I, Mongkolsapaya, Juthathip, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Screaton, Gavin R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687667/ https://www.ncbi.nlm.nih.gov/pubmed/34942101 http://dx.doi.org/10.1016/S0140-6736(21)02844-0

Ejemplares similares

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2021)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2016)

Anti-Dengue E-dimer epitope human antibodies have therapeutic activity against Zika virus infection
por: Fernandez, Estefania, et al.
Publicado: (2017)

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope
por: Rouvinski, Alexander, et al.
Publicado: (2017)

Lectin Switching During Dengue Virus Infection
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2011)

Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
por: Sheward, Daniel J, et al.
Publicado: (2022)

Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels
por: Harvala, Heli, et al.
Publicado: (2020)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Sensing of Immature Particles Produced by Dengue Virus Infected Cells Induces an Antiviral Response by Plasmacytoid Dendritic Cells
por: Décembre, Elodie, et al.
Publicado: (2014)

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021)

The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022)

Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
por: Grüne, Barbara, et al.
Publicado: (2022)

Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
por: Chun, June Young, et al.
Publicado: (2022)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022)

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
por: Andrews, Nick, et al.
Publicado: (2022)

Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
por: Carrazco-Montalvo, Andrés, et al.
Publicado: (2022)

A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
por: Manjunath, R, et al.
Publicado: (2022)

Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater
por: Ahmed, Warish, et al.
Publicado: (2022)

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
por: Chavda, Vivek P, et al.
Publicado: (2022)

The updated strategy to overcome new challenge: Omicron variant (B.1.1.529) pandemic
por: Ri, HyokJu, et al.
Publicado: (2022)

Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients
por: Spensley, Katrina J., et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!
por: Rahmani, Shayan, et al.
Publicado: (2022)

A study on the effect of natural products against the transmission of B.1.1.529 Omicron
por: Alkafaas, Samar Sami, et al.
Publicado: (2023)

First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador
por: Carrazco-Montalvo, A., et al.
Publicado: (2022)

Clinical Characteristics of Omicron (B.1.1.529) Variant in Children: A Multicenter Study in Spain
por: Molina Gutiérrez, Miguel Ángel, et al.
Publicado: (2022)

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months
por: Medigeshi, Guruprasad R, et al.
Publicado: (2022)

Recent advances in understanding dengue
por: Yacoub, Sophie, et al.
Publicado: (2016)

The immunology of Zika Virus
por: Culshaw, Abigail, et al.
Publicado: (2018)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat assessment and plan of action
por: Choudhary, Om Prakash, et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection
por: Elkoshi, Zeev
Publicado: (2022)

SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
por: Reynolds, Catherine J., et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
por: Mohseni Afshar, Zeinab, et al.
Publicado: (2023)

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)
por: Lu, Yuying, et al.
Publicado: (2023)

SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
por: Ciurkiewicz, M., et al.
Publicado: (2023)

CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever
por: Shu, Bo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4rsl4k3l31slh0a2qbia8k4q9e